FDA approved new indications for these drugs in July, include a Janus kinase inhibitor and a phosphodiesterase-4 inhibitor for use in dermatology, a carbonic anhydrase inhibitor for partial-onset seizures, and an expanded indication for the TKI crizotinib.

This case study describes an adult man with a history of diabetes and hypertension presenting with painful lesions on his arms and legs. The description covers the course of his workup for presumptive infectious dermatitis through differential diagnosis when the infectious disease workup revealed sterile lesions, to the final diagnosis of Sweet syndrome (acute febrile neutrophilic dermatosis).

More than 15 professional societies now recommend the use of icosapent ethyl to treat ASCVD, but clinical questions about the use of omega-3 fatty acids remain. Drs. Leslie Cho and Erin Michos discuss the role of DHA and EPA and whether all omega-3 fatty acids are the same. But what about EPA plasma levels, incidence of atrial fibrillation, and differences between the STRENGTH and REDUCE-IT trials? Tune in to get these answers and more in this 13-minute, 0.25-CME credit hours video podcast.

A detailed summarization of the clinical presentation of 197 individuals with PCR-confirmed diagnosis of monkeypox in the UK. The summary documents a highly variable prodrome in terms of prodromal symptoms and timing to eruption of visible lesions. Systemic illness was seen in 86% of patients. After mucocutaneous lesions, seen in 100% of patients, fever was the next most common manifestation, seen in 62% of patients.

Patients who survive severe intracerebral hemorrhage (ICH) and intraventricular hemorrhage (IVH) typically have poor functional outcome in the short term and understanding of future recovery has been limited. These findings indicate that hospital events significantly influenced long-term functional recovery after ICH and IVH, suggesting that aggressive ICH and IVH resolution and prevention of systemic complications and cerebral ischemic injury may promote better outcomes among patients with ICH and IVH with high clinical severity.

Kar-XT adds trospium to xanomeline to substantially improve the second agent’s tolerability, enabling its use to reduce both positive and negative symptoms in schizophrenia. Allopregnanolone, an oral version of brexanolone, is being investigated in MDD. The dextromethorphan and bupropion combo, AXS-05, seeks to offer a new antidepressant option and hydroxynorketamine promises MDD treatment without ketamine’s dissociative effects and abuse potential.